Results 1 to 10 of about 290,586 (152)

Racial and ethnic disparities in survival outcomes among patients with inflammatory breast cancer: a systematic review and meta-analysis [PDF]

npj Breast Cancer
Inflammatory breast cancer (IBC) is a rare and aggressive subtype of breast cancer characterized by rapid progression, early metastasis, and poor prognosis.
Chalothorn Wannaphut, Ben Ponvilawan, Toshiaki Iwase, Yoko Takahashi, Xiaoping Wang, Naoto T. Ueno   +5 more
doaj   +2 more sources

Inflammatory breast cancer, best practice in the community setting [PDF]

npj Breast Cancer
Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer typically diagnosed at advanced stages. Although many cases initially respond to conventional therapies, IBC remains refractory, with high risk of recurrence due to early ...
Yoko Takahashi, Nithya Sridhar, Toshiaki Iwase, Ashley Marumoto, Jami Fukui, Aiesha Pradhan, Yee Chung Cheng, Naoto T. Ueno   +7 more
doaj   +2 more sources

Clinicogenomic Characterization of Inflammatory Breast Cancer. [PDF]

Clin Cancer Res
Abstract Purpose: Inflammatory breast cancer (IBC) is a rare and clinically distinct form of breast cancer associated with poor outcomes. The biological mechanisms driving IBC remain poorly understood, partly due to limited large-scale genomic studies that directly compare IBC with non-IBC ...
Priedigkeit N, Harrison B, Shue R, Hughes ME, Li Y, Lebrón-Torres A, Kirkner GJ, Spurr LF, Remolano MC, Strauss S, Files J, Feeney AM, Grant L, Mohammed-Abreu A, Garrido-Castro A, Barroso-Sousa R, Bychkovsky B, Nakhlis F, Bellon JR, King TA, Winer EP, Lindeman N, Johnson BE, Sholl L, Dillon D, Overmoyer B, Tolaney SM, Cherniack AD, Lin NU, Lynce F.   +29 more
europepmc   +4 more sources

Pathological complete response to neoadjuvant TACHP in HER2-positive/HR-positive inflammatory breast cancer: a case report [PDF]

Frontiers in Oncology
Inflammatory breast cancer is a highly aggressive and locally advanced form of breast cancer with a poor prognosis. Neoadjuvant chemotherapy is the cornerstone of current treatment, aiming to downstage the disease and enable surgical intervention, which ...
Mengjie Guo, Guangjin Liu, Xin Han, Rui Jiao, Jinmao Li   +4 more
doaj   +2 more sources

INFLAMMATORY BREAST CANCER

European Journal of Breast Health, 2012
Inflammatory breast cancer is one of the rarest and most aggressive forms of breast cancer, having relatively distinct clinicopathological features and the lowest survival rates.
Abut Kebudi, Uğur Deveci
doaj   +5 more sources

Copy Number Variation in Inflammatory Breast Cancer

Cells, 2023
Identification of a unique genomic biomarker in de novo inflammatory breast cancer (IBC) may provide an insight into the biology of this aggressive disease. The goal of our study was to elucidate biomarkers associated with IBC.
Aditi Hazra, Andrea O’Hara, Kornelia Polyak, Faina Nakhlis, Beth T. Harrison, Antonio Giordano, Beth Overmoyer, Filipa Lynce   +7 more
doaj   +1 more source

PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening

Biomedicines, 2021
Human epidermal growth factor receptor (EGFR) 2 (HER2) is overexpressed/amplified in about 25% of all breast cancers, and EGFR is overexpressed in up to 76% and amplified in up to 24% of triple-negative breast cancers (TNBC).
Jangsoon Lee, Huey Liu, Troy Pearson, Toshiaki Iwase, Jon Fuson, Alshad S. Lalani, Lisa D. Eli, Irmina Diala, Debu Tripathy, Bora Lim, Naoto T. Ueno   +10 more
doaj   +1 more source

ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells

Biomedicines, 2021
Triple-negative breast cancer (TNBC) is a heterogeneous group of estrogen, progesterone, and HER2-negative breast cancers with poor clinical outcomes. The imipridone ONC201 is a G-protein-coupled dopamine receptor D2 modulator and an allosteric agonist ...
Bora Lim, Christine B. Peterson, Alexander Davis, Elin Cho, Troy Pearson, Huey Liu, Minha Hwang, Naoto Tada Ueno, Jangsoon Lee   +8 more
doaj   +1 more source

Update on systemic treatment for newly diagnosed inflammatory breast cancer

Journal of Advanced Research, 2021
Background: Inflammatory breast cancer (IBC) is a rare and aggressive disease, accounting for 2–4% of new cases of breast cancer. Owing to its aggressive nature, IBC represent approximately 8–10% of breast cancer deaths.
Sudpreeda Chainitikun, Sadia Saleem, Bora Lim, Vicente Valero, Naoto T. Ueno   +4 more
doaj   +1 more source

Decorin-mediated suppression of tumorigenesis, invasion, and metastasis in inflammatory breast cancer

Communications Biology, 2021
Xiaoding Hu et al. find that expression of the proteoglycan decorin is decreased in patients with inflammatory breast cancer compared to normal breast tissue and some other types of breast cancer.
Xiaoding Hu, Emilly S. Villodre, Richard Larson, Omar M. Rahal, Xiaoping Wang, Yun Gong, Juhee Song, Savitri Krishnamurthy, Naoto T. Ueno, Debu Tripathy, Wendy A. Woodward, Bisrat G. Debeb   +11 more
doaj   +1 more source